Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 6/20 | 0.54 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.53 |
| ▸ | NPY1R | P25929 | 3/20 | 0.53 |
| ▸ | NPY2R | P49146 | 3/20 | 0.53 |
| ▸ | NPY4R | P50391 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29666286 | 0.92 | GHSR (0.59) | GHSR | |
| SCHEMBL31316304 | 0.91 | GHSR (0.54) | GHSRC5AR1NPY1RNPY2RNPY4R | |
| SCHEMBL30309229 | 0.91 | GHSR (0.60) | GHSRNPY1RNPY2RNPY4R | |
| SCHEMBL29462005 | 0.90 | GHSR (0.58) | GHSRC5AR1NPY1RNPY2RNPY4R | |
| SCHEMBL29540499 | 0.90 | C5AR1 (0.58) | GHSRC5AR1NPY2R | |
| SCHEMBL29641153 | 0.90 | C5AR1 (0.58) | GHSRC5AR1NPY2R | |
| SCHEMBL29666294 | 0.89 | GHSR (0.56) | GHSR | |
| SCHEMBL29462003 | 0.89 | GHSR (0.54) | GHSRC5AR1NPY1RNPY2RNPY4R | |
| SCHEMBL30485843 | 0.89 | GHSR (0.57) | GHSRC5AR1NPY1RNPY2RNPY4R | |
| SCHEMBL29808394 | 0.89 | GHSR (0.63) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116004221-B | New application of cyclic peptide, acridine labeled complex, preparation method and detection kit | 湖南卓润生物科技有限公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-116004221-A | New application of cyclic peptide, acridine labeled complex, preparation method and detection kit | 湖南卓润生物科技有限公司 | 2023-04-25 | — | — | CN | disclosed |